Karyopharm Therapeutics Inc. KPTI Cash Flow

Karyopharm therapeutics inc. (KPTI)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14
Operating activities
Net loss
-186,360	-199,590	-209,153	-215,869	-206,109	-178,407	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-112,435	-	-111,688	-116,636	-119,173	-118,181	-115,063	-104,414	-88,150	-75,777	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
997	1,000	889	834	776	700	702	690	686	700	719	722	721	717	714	700	677	634	589	530	416	323	0	0	0
Net amortization of premiums and discounts on investments
848	1,382	1,493	1,209	653	-29	-564	-865	-1,080	-1,187	-1,263	-1,196	-1,152	-1,199	-1,274	-1,557	-1,861	-1,778	0	0	0	-	-	-	-
Amortization of debt discount and issuance costs
7,401	7,193	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation expense
16,536	15,291	15,639	16,694	17,018	17,275	17,877	17,971	18,660	20,405	21,032	21,758	23,034	22,283	22,501	20,389	18,466	17,057	16,304	15,737	15,143	14,240	0	0	0
Changes in operating assets and liabilities:
Accounts receivable
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inventory
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
539	868	516	2,236	4,622	4,663	2,715	1,362	235	-342	514	604	424	120	-1,437	-2,486	-1,075	55	-1,108	1,089	241	45	0	0	0
Operating lease right-of-use assets
-1,128	-1,094	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	470	0	0	0
Accounts payable
-574	-3,301	830	-2,681	-2,623	-1,380	351	546	658	909	-263	-795	129	945	-1,986	-411	-2,400	-2,426	2,035	1,029	3,231	4,496	0	0	0
Accrued expenses and other liabilities
15,117	8,512	3,685	5,051	7,705	11,255	11,786	10,210	10,863	10,070	5,690	1,782	2,152	368	3,265	2,390	1,783	5,766	5,446	7,262	5,763	4,445	0	0	0
Deferred revenue
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating lease liabilities
-1,375	-1,175	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-79	0	0	0
Deferred rent
-	-	-	-	-	-2,646	-1,332	-423	-219	280	0	0	0	-	-	561	443	-213	0	0	0	-	-	-	-
Net cash used in operating activities
-169,210	-190,822	-199,505	-201,664	-191,088	-159,117	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Investing activities
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-85,934	-	-84,768	-89,764	-96,969	-94,029	-86,421	-77,320	-61,103	-51,447	0	0	0
Purchases of property and equipment
167	206	1,249	1,633	2,030	2,363	0	0	0	-	-	-	-	70	550	687	1,277	1,416	1,010	3,159	2,887	2,834	0	0	0
Proceeds from maturities of investments
244,525	257,145	245,586	205,419	169,941	137,510	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of investments
244,378	178,489	235,478	214,536	246,068	242,811	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash (used in) provided by investing activities
-20	78,450	8,859	-10,750	-78,157	-107,664	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Financing activities
Increase in restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	400	0	0	0
Proceeds from maturities of investments
-	-	-	-	-	-	-	-	-	-	-	-	119,196	-	217,782	284,844	266,660	215,867	0	0	0	-	-	-	-
Purchases of investments
-	-	-	-	-	-	-	-	-	-	-	-	100,772	-	165,399	182,708	179,293	305,192	0	0	0	-	-	-	-
Net cash provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	18,393	-	51,836	101,367	86,008	-90,823	-188,562	-235,404	-236,586	-67,031	0	0	0
Proceeds from the exercise of stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock, net of issuance costs
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	92,084	0	0	0	-	-	-	-
Proceeds from the exercise of stock options and shares issued under employee stock purchase plan
7,086	4,505	2,016	2,225	3,242	3,519	3,022	2,396	1,230	858	0	0	0	-	-	-	-	616	535	571	441	284	0	0	0
Net cash provided by financing activities
288,982	124,305	257,145	169,095	315,832	316,109	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	51,025	-	33,399	1,959	1,736	92,700	91,365	204,665	204,268	113,121	0	0	0
Effect of exchange rate on cash, cash equivalents and restricted cash
-24	19	-95	-25	-158	-78	21	56	238	211	80	31	-98	-66	-58	-76	-40	-99	0	0	0	-	-	-	-
Net increase (decrease) in cash, cash equivalents and restricted cash
119,728	11,952	66,404	-43,344	46,429	49,250	47,373	63,739	11,735	19,345	10,549	17,666	-16,614	-8,698	409	13,486	-9,265	-92,251	-183,632	-108,076	-93,440	-5,365	0	0	0
Supplemental disclosures:
Operating lease right-of-use assets obtained in exchange for operating lease liabilities
-	11,711	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Property and equipment purchases included in accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Vesting of restricted common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	319	312	347	305	0	0	0
Deferred financing costs in accrued expenses
0	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	0	-	-	-	-
Cash paid for amounts included in the measurement of operating lease liabilities
3,055	2,889	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest on deferred royalty obligation
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-